IDEAYA Biosciences, Inc. Capital Expenditures
IDEAYA Biosciences, Inc. (IDYA) reported Capital Expenditures of $1.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-04
- IDEAYA Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $866.00K, a 30.62% increase year-over-year.
- IDEAYA Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $967.00K, a 27.29% decline year-over-year.
- IDEAYA Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $333.00K, a 69.78% decline year-over-year.
- IDEAYA Biosciences, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $42.00K, a 90.81% decline year-over-year.
- IDEAYA Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $2.37M, a 38.61% decline from fiscal 2024.
- IDEAYA Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $3.86M, a 62.88% increase from fiscal 2023.
- IDEAYA Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $2.37M, a 31.22% decline from fiscal 2022.
- IDEAYA Biosciences, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $3.44M, a 30.22% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $866.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.83M 10-Q · filed 2026-08-04 | $2.17M derived: sum of 3 quarters · filed 2026-08-04 | $2.21M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $967.00K 10-Q · filed 2026-05-05 | $1.30M derived: sum of 2 quarters · filed 2026-05-05 | $1.34M derived: sum of 3 quarters · filed 2026-05-05 | $2.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $333.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $375.00K derived: sum of 2 quarters · filed 2026-02-17 | $1.04M derived: sum of 3 quarters · filed 2026-08-04 | $2.37M 10-K · filed 2026-02-17 |
| 2025-09-30 | $42.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $705.00K derived: sum of 2 quarters · filed 2026-08-04 | $2.04M 10-Q · filed 2025-11-04 | $3.14M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $663.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.99M 10-Q · filed 2026-08-04 | $3.10M derived: sum of 3 quarters · filed 2026-08-04 | $3.55M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $1.33M 10-Q · filed 2026-05-05 | $2.43M derived: sum of 2 quarters · filed 2026-05-05 | $2.89M derived: sum of 3 quarters · filed 2026-05-05 | $3.86M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $1.56M derived: sum of 2 quarters · filed 2026-02-17 | $2.53M derived: sum of 3 quarters · filed 2026-02-17 | $3.86M 10-K · filed 2026-02-17 |
| 2024-09-30 | $457.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.43M derived: sum of 2 quarters · filed 2025-11-04 | $2.75M 10-Q · filed 2025-11-04 | $3.59M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $973.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $2.30M 10-Q · filed 2025-08-05 | $3.14M derived: sum of 3 quarters · filed 2026-02-17 | $3.74M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $1.32M 10-Q · filed 2025-05-06 | $2.16M derived: sum of 2 quarters · filed 2026-02-17 | $2.77M derived: sum of 3 quarters · filed 2026-02-17 | $3.65M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $838.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $1.44M derived: sum of 2 quarters · filed 2026-02-17 | $2.33M derived: sum of 3 quarters · filed 2026-02-17 | $2.37M 10-K · filed 2026-02-17 |
| 2023-09-30 | $603.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $1.49M derived: sum of 2 quarters · filed 2024-11-04 | $1.53M 10-Q · filed 2024-11-04 | $1.53M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $884.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $927.00K 10-Q · filed 2024-08-06 | $927.00K derived: sum of 3 quarters · filed 2025-02-18 | $2.03M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $43.00K 10-Q · filed 2024-05-07 | $43.00K derived: sum of 2 quarters · filed 2025-02-18 | $1.14M derived: sum of 3 quarters · filed 2025-02-18 | $3.08M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $1.10M derived: sum of 2 quarters · filed 2025-02-18 | $3.04M derived: sum of 3 quarters · filed 2025-02-18 | $3.44M 10-K · filed 2025-02-18 |
| 2022-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $3.04M derived: sum of 2 quarters · filed 2023-11-07 | $3.44M 10-Q · filed 2023-11-07 | $4.05M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.34M 10-Q · filed 2023-08-10 | $2.95M derived: sum of 3 quarters · filed 2024-02-20 | $3.40M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $401.00K 10-Q · filed 2023-05-09 | $1.01M derived: sum of 2 quarters · filed 2024-02-20 | $1.46M derived: sum of 3 quarters · filed 2024-02-20 | $2.04M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $605.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $1.06M derived: sum of 2 quarters · filed 2024-02-20 | $1.64M derived: sum of 3 quarters · filed 2024-02-20 | $2.64M 10-K · filed 2024-02-20 |
| 2021-09-30 | $458.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.04M derived: sum of 2 quarters · filed 2022-11-08 | $2.04M 10-Q · filed 2022-11-08 | $2.22M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $578.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $1.58M 10-Q · filed 2022-08-15 | $1.76M derived: sum of 3 quarters · filed 2023-03-07 | $2.00M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | $1.00M 10-Q · filed 2022-05-10 | $1.18M derived: sum of 2 quarters · filed 2023-03-07 | $1.43M derived: sum of 3 quarters · filed 2023-03-07 | |
| 2020-12-31 | $179.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $424.00K derived: sum of 2 quarters · filed 2023-03-07 | $493.00K 10-K · filed 2023-03-07 | |
| 2020-09-30 | $245.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $314.00K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $69.00K 10-Q · filed 2021-08-10 | |||
| 2019-12-31 | $216.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $298.00K derived: sum of 2 quarters · filed 2022-03-18 | $747.00K derived: sum of 3 quarters · filed 2022-03-18 | $1.35M 10-K · filed 2022-03-18 |
| 2019-09-30 | $82.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $531.00K derived: sum of 2 quarters · filed 2020-11-12 | $1.14M 10-Q · filed 2020-11-12 | $1.45M derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-06-30 | $449.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $1.05M 10-Q · filed 2020-08-12 | $1.36M derived: sum of 3 quarters · filed 2021-03-23 | $2.36M derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-03-31 | $606.00K 10-Q · filed 2020-05-12 | $914.00K derived: sum of 2 quarters · filed 2021-03-23 | $1.92M derived: sum of 3 quarters · filed 2021-03-23 | |
| 2018-12-31 | $308.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $1.31M derived: sum of 2 quarters · filed 2021-03-23 | $1.71M 10-K · filed 2021-03-23 | |
| 2018-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $1.40M 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | $399.00K 10-Q · filed 2019-08-12 | |||
| 2017-12-31 | $1.76M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |